Aurobindo Pharma Subsidiary Launches Pomalidomide in US; Targets $3.3B Market

Pomalidomide Capsules, manufactured by Eugia Pharma Specialities Limited, are now available in the US market, targeting an estimated US$ 3.3 billion opportunity.
Eugia Pharma was among the first to file an Abbreviated New Drug Application (ANDA) for this product, positioning it strategically in a key oncology segment.

What just happened (today’s filing)

Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma, has successfully launched Pomalidomide Capsules in the United States.

The drug is available in four strengths: 1 mg, 2 mg, 3 mg, and 4 mg. It is a generic equivalent to Celgene's Pomalyst® Capsules.

The launch targets a significant US market estimated at US$ 3.3 billion for the twelve months ending January 2026.

Eugia Pharma's position as one of the earliest ANDA filers for Pomalidomide Capsules provides a strategic advantage in this competitive segment.

Why this matters

This launch signifies Aurobindo Pharma's strategic expansion into the lucrative US market with a high-value specialty oncology drug.

It leverages Eugia Pharma's capabilities in developing complex generics and its first-to-file status, aiming to capture market share in a segment vital for treating multiple myeloma and Kaposi sarcoma.

The entry into this market is crucial for Aurobindo's continued growth and diversification in its largest operating geography.

The backstory (grounded)

Eugia Pharma Specialities Limited secured final USFDA approval for Pomalidomide Capsules on October 30, 2020.

Aurobindo Pharma itself is a major player in the US generics market, ranking as the largest by prescriptions dispensed. Its US subsidiary, APUSA, handles sales and marketing, distributing a wide range of generic pharmaceuticals.

The company has a stated strategy to expand its portfolio with high-value products like oncology drugs.

What changes now

Shareholders can anticipate enhanced market access for Aurobindo Pharma in the US specialty oncology segment.

The launch diversifies Eugia Pharma's product portfolio, potentially leading to new revenue streams.

It reinforces Aurobindo's positioning as a key supplier of complex generics in the critical US healthcare market.

Risks to watch

Aurobindo Pharma has faced regulatory scrutiny. It received a SEBI warning letter in June 2022 for inadequate disclosure of US FDA audit details.

Recently, Eugia Pharma's Unit-III facility received 11 procedural observations from the US FDA in February 2026. Aurobindo's Unit-VII also underwent an FDA inspection with data integrity and hygiene flags around the same time.

The company and its subsidiary have been involved in patent litigation related to Pomalidomide generics, facing allegations of anti-competitive practices.

Peer comparison

Indian pharmaceutical giants like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Cipla are also aggressively pursuing opportunities in the US oncology generics market.

Competitors such as Natco Pharma recently launched Pomalidomide Capsules in the US market, highlighting the intense competition and the drug's market significance.

These companies are increasingly focusing on complex generics and specialty therapies to gain an edge in the lucrative, albeit competitive, US healthcare landscape.

Context metrics (time-bound)

• The US market for branded Pomalyst® recorded estimated sales of USD 3.3 billion for the twelve months ending January 2026 [filing].

What to track next

Investors will monitor market uptake and sales performance for Pomalidomide Capsules against competitors.

Future product launches from Eugia Pharma and Aurobindo's R&D pipeline in specialty therapeutics will be key.

Any further regulatory developments concerning US FDA inspections or quality compliance will be critical to observe.

The response from competing generic players and the branded drug manufacturer will shape market dynamics.